Macro CD5L⁺ deteriorates CD8⁺T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.

ABSTRACT: Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR profiles of 18 tumor tissues pre- and post- therapy of gemcitabine plus oxaliplatin, in combination with lenvatinib and anti-PD1 antibody for intrahepatic cholangiocarcinoma. We find that high CD8 GZMB⁺ and CD8 proliferating proportions and a low Macro CD5L⁺ proportion predict good response to the therapy. In patients with a poor response, the CD8 GZMB⁺ and CD8 proliferating proportions are increased, but the CD8 GZMK⁺ proportion is decreased after the therapy. Transition of CD8 proliferating and CD8 GZMB

SUBMITTER: Lu JC 

PROVIDER: S-EPMC10799889 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature